Cybin's CYB003 Phase 3 (APPROACH/EMBRACE) topline in MDD reports a statistically significant MADRS reduction on primary endpoint before year-end, but FDA will still require the second confirmatory study.

Cybin, a psychedelic drug company, is running a major clinical trial called APPROACH/EMBRACE for their drug CYB003 — a modified form of psilocin (the active ingredient in magic mushrooms) — in people with major depression (MDD). The trial is expected to show the drug meaningfully reduces depression symptoms. But even a clear win won't be enough: the FDA requires two separate successful trials before it will approve any drug, so Cybin still has more work to do.

Deuterated analog durability data looks real, but my role demands two adequate well-controlled trials. One positive readout doesn't shortcut the NDA.